Generalized Anxiety Disorder Gad Market

DelveInsight’s ‘Generalized Anxiety Disorder (GAD) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Generalized Anxiety Disorder (GAD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Generalized Anxiety Disorder (GAD) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Generalized Anxiety Disorder (GAD) market size from 2019–2032, segmented by seven major markets. The report also covers the current Generalized Anxiety Disorder (GAD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Generalized Anxiety Disorder (GAD): Disease Understanding and Treatment Algorithm

Generalized Anxiety Disorder (GAD) Overview

Generalized anxiety disorder involves persistent and excessive worry that interferes with daily activities. This ongoing worry and tension may be accompanied by physical symptoms, such as restlessness, feeling on edge or easily fatigued, difficulty concentrating, muscle tension, or problems sleeping. Often the worries focus on everyday things such as job responsibilities, family health, or minor matters such as chores, car repairs, or appointments.

 

GAD can go undiagnosed because of a focus on physical symptoms and the stigma of mental illness. However, people with GAD can have meaningful lives and can function socially as well, when the anxiety level is mild-to-moderate or when they are taking some kind of treatment.

 

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) lists separation anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and an anxiety disorder caused by another medical condition.

 

The criteria of GAD in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months, with at least three of the core symptoms in adults and one sign in the case of children.

 

According to the Anxiety and Depression Association of America (ADAA), in any given year, GAD affects 6.8 million adults or 3.1% of the US population. Women are twice as likely to be affected. Although the exact cause of GAD is unknown, there is evidence that biological factors, family background, and life experiences, particularly stressful ones, play a role.

 

Generalized Anxiety Disorder (GAD) Diagnosis and Treatment

The DelveInsight Generalized Anxiety Disorder (GAD) Market Report gives a thorough understanding of Generalized Anxiety Disorder (GAD) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis.

 

It covers the details of conventional and current medical therapies and diagnoses available in the Generalized Anxiety Disorder (GAD) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Generalized Anxiety Disorder (GAD) Epidemiology

The Generalized Anxiety Disorder (GAD) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed prevalent patient pool, trends, and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Generalized Anxiety Disorder (GAD) epidemiology segmented as the 12-month prevalent cases of generalized anxiety disorder, gender-specific cases of generalized anxiety disorder, severity-specific cases of generalized anxiety disorder, and age-specific cases of generalized anxiety disorder. The report includes the diagnosed prevalent scenario of Generalized Anxiety Disorder (GAD) symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019–2032.

Country-wise Generalized Anxiety Disorder (GAD) Epidemiology

The epidemiology segment also provides the Generalized Anxiety Disorder (GAD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 12-month prevalent patient population of GAD in the 7MM countries was close to 16 million cases in 2021.

Generalized Anxiety Disorder (GAD) Drug Chapters

The drug chapter segment of the Generalized Anxiety Disorder (GAD) report encloses the detailed analysis of Generalized Anxiety Disorder (GAD) marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Generalized Anxiety Disorder (GAD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The evidence-based guideline summarizes recommendations on using cognitive-behavioral therapy (CBT) as first-line psychotherapy and recommends SSRIs and SNRIs for first-line pharmacotherapy. WFSBP specifically states that psychologic and pharmacologic therapies are often concomitant rather than alternative options.

Product details in the report…

 

Generalized Anxiety Disorder (GAD) Emerging Drugs

To meet the current demands of the patient pool and to counter the unmet needs of the therapeutic market, drug developers are gradually shifting their attention toward GAD as a possible indication for new targeted therapies.

 

Several companies are working robustly on many new therapies, such as MM-120 (Mind Med) and PH49B (VistaGen’s Therapeutics). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.

 

MM-120 (Mind Med) is a pharmacologically optimized form of lysergic acid diethylamide (LSD; it has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions). The drug is a psychedelic drug being developed for GAD and other brain-based disorders and can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM-120 manifests primarily in visual, as well as auditory, hallucinations. MM-120 is currently in Phase II b clinical trial for GAD. MindMed is working with study investigators and clinical trial sites to prepare for participant enrollment, which is expected to start in early 2022.

 

PH49B (VistaGen’s Therapeutics) is an innovative synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel mechanism of action, PH94B is an odorless nasal spray administered at microgram-level doses to achieve rapid-onset anti-anxiety, or anxiolytic, effects. The pharmacological activity of PH94B is fundamentally differentiated from that of all FDA-approved anti-anxiety drugs. Importantly, PH94B does not require systemic uptake and distribution to produce its rapid-onset anti-anxiety effects. In all clinical trials to date, PH94B’s safety profile has been excellent, with placebo-like side effects and no serious adverse events like those that are associated with the current FDA-approved treatment options. The drug is currently in Phase II for the treatment of generalized anxiety disorder.

Product details in the report…

Generalized Anxiety Disorder (GAD) Market Outlook

The Generalized Anxiety Disorder (GAD) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Generalized Anxiety Disorder (GAD) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the Generalized Anxiety Disorder (GAD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Generalized Anxiety Disorder (GAD) market in the 7MM is expected to change in the study period 2019–2032.

 

Key Findings

This section includes a glimpse of the Generalized Anxiety Disorder (GAD) market in the 7MM. The Generalized Anxiety Disorder (GAD) market size in the seven major markets was approximately USD 1,500 million in 2021.

 

The United States: Market Outlook

This section provides the total Generalized Anxiety Disorder (GAD) market size and market size of Generalized Anxiety Disorder (GAD) by therapies in the United States.

 

Among the pharmacological therapies, SSRIs (Paroxetine, Escitalopram, Sertraline, Fluoxetine, and others) are commonly used as the first line of therapy. They can relieve anxiety symptoms and help reduce the symptoms of depression that often accompany anxiety disorders. Side effects of SSRIs include nausea, insomnia, and sexual dysfunction. If treatment with SSRIs does not work, other classes of medications, such as SNRIs, which include duloxetine and venlafaxine, and others are recommended. They have a similar effect to SSRIs.

 

Pregabalin is also approved for the treatment of GAD; although this medication is effective, it often causes dizziness and tiredness. Buspirone can relieve anxiety, but it has not been studied well as other medications. So it is usually suggested if SSRIs are not effective or well tolerated. The possible side effects of Buspirone include drowsiness, nausea, and sleep problems.

 

Benzodiazepines are sedatives that also help relieve anxiety. They have a fast effect, but they risk becoming dependent on them after a few weeks of use. For this reason, benzodiazepines are not recommended for the treatment of GAD.

 

Despite the availability of these therapies, there is a lack of efficient therapeutic agents as the available therapies have safety issues over older medication classes, though they may have a slow onset of action, and patients may experience troublesome side effects. Therefore, there is a high unmet need for developing safe and effective therapies.

 

PH94B is an innovative synthetic investigational neurosteroid developed from proprietary compounds and has already demonstrated efficacy in a small, exploratory, placebo-controlled Phase II clinical study in patients with GAD. The company believes that these transient anti-anxiety effects of PH94B may warrant further investigation in a larger Phase II GAD trial.

 

The United States accounts for the highest market size of Generalized Anxiety Disorder (GAD) compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Generalized Anxiety Disorder (GAD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total Generalized Anxiety Disorder (GAD) market size and market size by therapies of Generalized Anxiety Disorder (GAD) in Japan are also mentioned.

Generalized Anxiety Disorder (GAD) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Generalized Anxiety Disorder (GAD) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Generalized Anxiety Disorder (GAD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stages. It also analyses Generalized Anxiety Disorder (GAD)’s key players involved in developing targeted therapeutics.

 

Major players include MindMed, VistaGen, and others whose key products are expected to get launched in the US market by 20XX.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Generalized Anxiety Disorder (GAD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Generalized Anxiety Disorder (GAD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapy treatment patterns or Generalized Anxiety Disorder (GAD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Generalized Anxiety Disorder (GAD) market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Generalized Anxiety Disorder (GAD), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight is provided into the Generalized Anxiety Disorder (GAD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Generalized Anxiety Disorder (GAD) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Generalized Anxiety Disorder (GAD) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Generalized Anxiety Disorder (GAD) market

Report Highlights

  • In the coming years, the Generalized Anxiety Disorder (GAD) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder (GAD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Generalized Anxiety Disorder (GAD). The launch of emerging therapies will significantly impact the Generalized Anxiety Disorder (GAD) market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Generalized Anxiety Disorder (GAD).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Generalized Anxiety Disorder (GAD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Generalized Anxiety Disorder (GAD) Pipeline Analysis
  • Generalized Anxiety Disorder (GAD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Generalized Anxiety Disorder (GAD) Report Key Strengths

  • 11-year Forecast
  • 7MM Coverage
  • Generalized Anxiety Disorder (GAD) Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Generalized Anxiety Disorder (GAD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the market share (%) distribution, and how would it look in 2032?
  • What would be the Generalized Anxiety Disorder (GAD) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Generalized Anxiety Disorder (GAD) market Size during the forecast period (2019–2032)?
  • At what CAGR is the Generalized Anxiety Disorder (GAD) market expected to grow in the 7MM during the forecast period (2019–2032)?
  • What would be the Generalized Anxiety Disorder (GAD) market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the Generalized Anxiety Disorder (GAD) market growth till 2032 and the resultant market size in 2032?
  • How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Generalized Anxiety Disorder (GAD)?
  • What is the historical patient pool of Generalized Anxiety Disorder (GAD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Generalized Anxiety Disorder (GAD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Generalized Anxiety Disorder (GAD)?
  • Out of all 7MM countries, which country would have the highest 12-month prevalence of Generalized Anxiety Disorder (GAD) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of the Generalized Anxiety Disorder (GAD)?
  • What are the current treatment guidelines for treating Generalized Anxiety Disorder (GAD) in the US, Europe, and Japan?
  • What are the Generalized Anxiety Disorder (GAD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies to treat Generalized Anxiety Disorder (GAD)?
  • How many therapies are developed by each company for the treatment of the Generalized Anxiety Disorder (GAD)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat the Generalized Anxiety Disorder (GAD)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Generalized Anxiety Disorder (GAD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies for Generalized Anxiety Disorder (GAD) and its status?
  • Which key designations have been granted for the emerging therapies for Generalized Anxiety Disorder (GAD)?
  • What are the global historical and forecasted markets for Generalized Anxiety Disorder (GAD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Generalized Anxiety Disorder (GAD) market
  • To understand the future market competition in the Generalized Anxiety Disorder (GAD) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder (GAD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Generalized Anxiety Disorder (GAD) market.
  • To understand the future market competition in the Generalized Anxiety Disorder (GAD) market.

1. Key Insights

2. Report Introduction

3. Generalized Anxiety Disorder Market Overview at a Glance

3.1. Market Share (%) Distribution of GAD in 2019

3.2. Market Share (%) Distribution of GAD in 2032

4. Executive Summary of Generalized Anxiety Disorder

5. Disease Background and Overview

5.1. Introduction

5.2. Causes and Risk Factors

5.3. Signs and Symptoms

5.4. Pathophysiology

5.5. Diagnosis

5.6. Screening Tools

5.7. Treatment and Management of Generalized Anxiety Disorder

5.7.1. Treatment of special populations

5.7.2. Treatment Guidelines

5.7.3. National Institute for Health and Care Excellence (NICE): GAD Management

5.7.4. Treatment Recommendation Summary

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total 12-month Diagnosed Prevalent Cases of GAD

6.3. Epidemiology of Generalized Anxiety Disorder

6.4. The United States

6.4.1. Total 12-month Diagnosed Prevalent Cases of GAD in the United States

6.4.2. Gender-specific cases of GAD in the United States

6.4.3. Age-specific cases of GAD in the United States

6.4.4. Severity-specific cases of GAD in the United States

6.5. EU-5

6.5.1. EU-5 Total 12-month Diagnosed Prevalent Cases of GAD

6.5.2. Germany

6.5.2.1. Gender-specific cases of GAD in Germany

6.5.2.2. Age-specific cases of GAD in Germany

6.5.2.3. Severity-specific cases of GAD in Germany

6.5.3. France

6.5.3.1. Gender-specific cases of GAD in France

6.5.3.2. Age-specific cases of GAD in France

6.5.3.3. Severity-specific cases of GAD in France

6.5.4. Italy

6.5.4.1. Gender-specific cases of GAD in Italy

6.5.4.2. Age-specific cases of GAD in Italy

6.5.4.3. Severity-specific cases of GAD in Italy

6.5.5. Spain

6.5.5.1. Gender-specific cases of GAD in Spain

6.5.5.2. Age-specific cases of GAD in Spain

6.5.5.3. Severity-specific cases of GAD in Spain

6.5.6. The United Kingdom

6.5.6.1. Gender-specific cases of GAD in the United Kingdom

6.5.6.2. Age-specific cases of GAD in the United Kingdom

6.5.6.3. Severity-specific cases of GAD in the United Kingdom

6.6. Japan

6.6.1. Total 12-month Diagnosed Prevalent Cases of GAD in Japan

6.6.2. Gender-specific cases of GAD in Japan

6.6.3. Age-specific cases of GAD in Japan

6.6.4. Severity-specific cases of GAD in Japan

7. Patient Journey of GAD

8. Emerging Drugs

8.1. MM-120: MindMed

8.1.1. Drug Description

8.1.2. Clinical Development

8.1.3. Product Profile

8.1.4. Analyst Views

8.2. PH94B: VistaGen Therapeutics

8.2.1. Product Description

8.2.2. Other Development Activities

8.2.3. Safety and Efficacy

8.2.4. Product Profile

8.2.5. Analyst Views

9. Pipeline Assets (with no recent development)

9.1. Vilazodone (Viibryd): Actavis

9.1.1. Drug Description

9.1.2. Other Development Activities

9.1.3. Clinical Development

9.1.4. Clinical Trials Information

9.1.5. Safety and Efficacy

9.1.6. Product Profile

9.2. Intuniv (Guanfacine): Takeda Pharmaceuticals

9.2.1. Drug Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Clinical Trials Information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.3. BNC210: Bionomics

9.3.1. Drug Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Safety and Efficacy

9.3.6. Product Profile

10. Generalized Anxiety Disorder: Seven Major Market Analysis

10.1. Key Findings

10.2. Market Size of Generalized Anxiety Disorder in 7MM

10.3. Market Outlook

10.4. The United States Market Size

10.4.1. Total Market Size of Generalized Anxiety Disorder in the US

10.4.2. Market Size of Generalized Anxiety Disorder by Therapies in the United States

10.5. EU-5 Market Size of Generalized Anxiety Disorder

10.5.1. Market Size of Generalized Anxiety Disorder by Therapies in Germany

10.5.2. Market Size of Generalized Anxiety Disorder by Therapies in France

10.5.3. Market Size of Generalized Anxiety Disorder by Therapies in Italy

10.5.4. Market Size of Generalized Anxiety Disorder by Therapies in Spain

10.5.5. Market Size of Generalized Anxiety Disorder by Therapies in the UK

10.6. Japan Market Size

10.6.1. Total Market Size of Generalized Anxiety Disorder in Japan

10.6.2. Market Size of Generalized Anxiety Disorder by Therapies in Japan

11. KOL Views

12. Unmet Needs

13. SWOT Analysis

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of Generalized Anxiety Disorder, Market, Epidemiology, and Key Events (2019–2032)

Table 2: “Normal” Worry Versus Generalized Anxiety Disorder

Table 3: Characteristics to Define GAD in DSM-V

Table 4: Evolution of the Definition of GAD in Succeeding Editions Of the DSM and ICD

Table 5: Treatment Approach to GAD

Table 6: The Stepped-care model

Table 7: Treatment Recommendations Summary

Table 8: Total 12-month Diagnosed Prevalent Cases of GAD in 7MM (2019–2032)

Table 9: Total 12-month Diagnosed Prevalent Cases of GAD in the United States (2019–2032)

Table 10: Gender-specific cases of GAD in the United States (2019–2032)

Table 11: Age-specific cases of GAD in the United States (2019–2032)

Table 12: Severity-specific cases of GAD in the United States (2019–2032)

Table 13:  Total 12-month Diagnosed Prevalent Cases of GAD in EU-5 (2019–2032)

Table 14: Gender-specific cases of GAD in Germany (2019–2032)

Table 15: Age-specific cases of GAD in Germany (2019–2032)

Table 16: Severity-specific cases of GAD in Germany (2019–2032)

Table 17: Gender-specific cases of GAD in France (2019–2032)

Table 18: Age-specific cases of GAD in France (2019–2032)

Table 19: Severity-specific cases of GAD in France (2019–2032)

Table 20: Gender-specific cases of GAD in Italy (2019–2032)

Table 21: Age-specific cases of GAD in Italy (2019–2032)

Table 22: Severity-specific cases of GAD in Italy (2019–2032)

Table 23: Gender-specific cases of GAD in Spain (2019–2032)

Table 24: Age-specific cases of GAD in Spain (2019–2032)

Table 25: Severity-specific cases of GAD in Spain (2019–2032)

Table 26: Gender-specific cases of GAD in the United Kingdom (2019–2032)

Table 27: Age-specific cases of GAD in the United Kingdom (2019–2032)

Table 28: Severity-specific cases of GAD in the United Kingdom (2019–2032)

Table 29: Total 12-month Diagnosed Prevalent Cases in Japan (2019–2032)

Table 30: Gender-specific cases of GAD in Japan (2019–2032)

Table 31: Age-specific cases of GAD in Japan (2019–2032)

Table 32: Severity-specific cases of GAD in Japan (2019–2032)

Table 33: Vilazodone, Clinical Trial Description, 2022

Table 34: Intuniv, Clinical Trial Description, 2022

Table 35: BNC210, Clinical Trial Description, 2022

Table 36: Seven Major Market Size of Generalized Anxiety Disorder in USD million (2019–2032f)

Table 37: Market Size of Generalized Anxiety Disorder in the United States in USD million (2019–2032)

Table 38: The US Market Size of Generalized Anxiety Disorder by Therapies in USD million (2019–2032)

Table 39: EU5 Market Size of Generalized Anxiety Disorder in USD million (2019–2032)

Table 40: Market Size of Generalized Anxiety Disorder by Therapies in Germany in USD million (2019–2032)

Table 41: Market Size of Generalized Anxiety Disorder by Therapies in France in USD million (2019–2032)

Table 42: Market Size of Generalized Anxiety Disorder by Therapies in Italy in USD million (2019–2032)

Table 43: Market Size of Generalized Anxiety Disorder by Therapies in Spain in USD million (2019–2032)

Table 44: Market Size of Generalized Anxiety Disorder by Therapies in the United Kingdom in USD million (2019–2032)

Table 45: Market Size of Generalized Anxiety Disorder in Japan in USD million (2019–2032)

Table 46: Market Size of Generalized Anxiety Disorder by Therapies in Japan in USD million (2019–2032)

List of Figures

Figure 1: Overview of GAD

Figure 2: Etiology of GAD

Figure 3: Risk factors for GAD

Figure 4: Symptoms and Behaviors Associated With Generalized Anxiety Disorder

Figure 5: Anxiety Triggers

Figure 6: Mental Disorders Screening – General Anxiety Disorder Assessment (GAD-7)

Figure 7: Mental Disorders Screening – Generalized Anxiety Disorder 2-item (GAD-2)

Figure 8: GAD Treatment Flow chart

Figure 9: Cognitive Behavioral Therapy

Figure 10: Pharmacotherapy for GAD

Figure 11: GAD Management Overview

Figure 12: Total 12-month Diagnosed Prevalent Cases of GAD in 7MM (2019–2032)

Figure 13: Total 12-month Diagnosed Prevalent Cases of GAD in the United States (2019–2032)

Figure 14: Gender-specific cases of GAD in the United States (2019–2032)

Figure 15: Age-specific cases of GAD in the United States (2019–2032)

Figure 16: Severity-specific cases of GAD in the United States (2019–2032)

Figure 17: Total 12-month Diagnosed Prevalent Cases of GAD in EU-5 (2019–2032)

Figure 18: Gender-specific cases of GAD in Germany (2019–2032)

Figure 19: Age-specific cases of GAD in Germany (2019–2032)

Figure 20: Severity-specific cases of GAD in Germany (2019–2032)

Figure 21: Gender-specific cases of GAD in France (2019–2032)

Figure 22: Age-specific cases of GAD in France (2019–2032)

Figure 23: Severity-specific cases of GAD in France (2019–2032)

Figure 24: Gender-specific cases of GAD in Italy (2019–2032)

Figure 25: Age-specific cases of GAD in Italy (2019–2032)

Figure 26: Severity-specific cases of GAD in Italy (2019–2032)

Figure 27: Gender-specific cases of GAD in Spain (2019–2032)

Figure 28: Age-specific cases of GAD in Spain (2019–2032)

Figure 29: Severity-specific cases of GAD in Spain (2019–2032)

Figure 30: Gender-specific cases of GAD in the United Kingdom (2019–2032)

Figure 31: Age-specific cases of GAD in the United Kingdom (2019–2032)

Figure 32: Severity-specific cases of GAD in the United Kingdom (2019–2032)

Figure 33: Total 12-month Diagnosed Prevalent Cases in Japan (2019–2032)

Figure 34: Gender-specific cases of GAD in Japan (2019–2032)

Figure 35: Age-specific cases of GAD in Japan (2019–2032)

Figure 36: Severity-specific cases of GAD in Japan (2019–2032)

Figure 36: Seven Major Market Size of Generalized Anxiety Disorder Disease in USD million (2019–2032)

Figure 37: Market Size of Generalized Anxiety Disorder in the United States in USD million (2019–2032)

Figure 38: Market Size of Generalized Anxiety Disorder in the United States by Therapies (2019–2032)

Figure 39: EU5 Market Size of Generalized Anxiety Disorder in USD million (2019–2032)

Figure 40: Market Size of Generalized Anxiety Disorder in Germany by Therapies (2019–2032)

Figure 41: Market Size of Generalized Anxiety Disorder in France by Therapies (2019–2032)

Figure 42: Market Size of Generalized Anxiety Disorder in Italy by Therapies (2019–2032)

Figure 43: Market Size of Generalized Anxiety Disorder in Spain by Therapies (2019–2032)

Figure 44: Market Size of Generalized Anxiety Disorder in the United Kingdom by Therapies (2019–2032)

Figure 45: Market Size of Generalized Anxiety Disorder in Japan in USD million (2019–2032)

Figure 46: Market Size of Generalized Anxiety Disorder in Japan by Therapies (2019–2032)

MindMed
VistaGen Therapeutics
Actavis
Takeda Pharmaceuticals
Bionomics

 

Forward to Friend

Need A Quote